Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Mechelen, Belgium and Paris, France, 15 OCTOBER 2020, 22.01 CET; regulated information –Servier and Galapagos NV (Euronext & NASDAQ: GLPG) report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086.
ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in 932 patients with knee osteoarthritis (OA) over 52 weeks of treatment. The study population was aged between 40 to 76 years (mean age was 63), mainly female (70%), and with a mean disease duration of 7 years.
The primary objective of ROCCELLA was to demonstrate the efficacy of at least one dose of GLPG1972/S201086 compared to placebo after 52 weeks of treatment in reducing cartilage loss of the central medial tibiofemoral compartment of the target knee via quantitative MRI.
The trial failed to meet the primary objective. The change from baseline to week 52 in cartilage thickness, in mm (SD) was -0.116 (0.27) for the placebo group and -0.068 (0.20), -0.097 (0.27) and -0.085 (0.22), for the low, medium and high dose, respectively. Statistically significant difference versus placebo was not reached in any of the treated groups.
There was no significant difference compared to placebo observed on secondary endpoints, including clinical outcomes.
Additional analyses are being conducted to fully evaluate the results, which will be presented at upcoming medical conferences.
GLPG1972/S201086 was generally well-tolerated by patients in this Phase 2 trial.
“While we are disappointed that ADAMTS-5 inhibition by GLPG1972/S201086 proved not to make a difference in this trial,we want to express our gratitude to all participating patients and investigators. This study result, while not what we hoped for, does add to the body of knowledge to help fight OA, a disease with substantial unmet medical need,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.
“We are pleased to have performed this study with Galapagos. Unfortunately, the ROCCELLA results provided insufficient evidence of GLPG1972/S201086 efficacy in patients with knee osteoarthritis. We acknowledge the importance of assessing this innovative mechanism of action in the clinical setting and we will continue analyzing the data for better knowledge of the disease for the benefit of the patients and for future developments. We would like also to thank all patients and investigators for participating in this very important study,” said Dr. Patricia Belissa-Mathiot, Director of Clinical Development and R&D Chief Medical Officer at Servier.
About the ROCCELLA trial
ROCCELLA was a multi-regional, randomized, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in patients with knee osteoarthritis. ROCCELLA included 932 patients in 12 countries in Europe, Asia, North and South America. Galapagos was responsible for ROCCELLA in the United States, where 326 patients were recruited. Servier was responsible for this trial in 11 countries, where 606 patients were recruited.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, oncology and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com.
|Investor contacts Galapagos:|
+1 781 460 1784
Sofie Van Gijsel
Senior Director IR
+32 485 19 14 15
|Media contacts Galapagos:|
Global Head of Communications & Public Affairs
+32 473 82 48 74
Senior Communications Director - Therapeutic Areas
+44 7717 801900
Galapagos forward-looking statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to diﬀer materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that ongoing and future clinical studies with GLPG1972/S201086 may not be completed in the currently envisaged timelines or at all, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of GLPG1972/S201086 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including our collaboration partner for GLPG1972/S201086, Servier) and that Galapagos’ estimations regarding its GLPG1972/S201086 development program and regarding the commercial potential of GLPG1972/S201086, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Composition of the Nomination Committee of Orion Corporation21.10.2020 17:40:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE 21 OCTOBER 2020 at 6.40 p.m. EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company: Annika EkmanPetteri KarttunenTimo MaasiltaMikael Silvennoinen Heikki WesterlundJukka Ylppö Heikki Westerlund was elected Chairman of the Committee. The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website. Orion Corporation Timo Lappalainen President and CEO Olli Huotari SVP, Corporate Functions Contact person: Timo Lapp
Norsk Hydro: REMINDER - Hydro’s third quarter results 202021.10.2020 16:30:00 CEST | Press release
Hydro's third quarter results 2020 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC), on Friday October 23, 2020. The quarterly report and presentation slides will be available on www.hydro.com at the same time. President & CEO Hilde Merete Aasheim and EVP & CFO Pål Kildemo will host an audio webcast and a conference call, in English, at 08:30 CEST the same day. Due to the Covid-19 situation, there will be no analyst and press conference at our corporate headquarters. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. See details below (it will not be possible to ask questions on the audio webcast). To join the conference call, please use the “Click to Join” link below 5-10 minutes prior to start time. You will be asked to enter your phone number and registration details. The Event Confer
Norsk Hydro: PÅMINNELSE - Presentasjon av Hydros resultat for tredje kvartal 202021.10.2020 16:30:00 CEST | Pressemelding
Hydros resultat for tredje kvartal 2020 blir offentliggjort fredag 23. oktober 2020 kl. 07.00 (norsk tid). Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Konsernsjef Hilde Merete Aasheim og konserndirektør for økonomi og finans Pål Kildemo vil presentere resultatet på engelsk samme dag kl. 08.30 (norsk tid) via audio webcast og telefonkonferanse. Pga. Covid-19-situasjonen vil det ikke bli pressekonferanse ved vårt hovedkontor. Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor (det vil ikke være mulig å stille spørsmål via audio webcast). Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg t
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING21.10.2020 16:20:00 CEST | Press release
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-10-23 Transaction type:SEK CreditTender date:2020-10-23Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-10-27Final repayment date2024-10-28Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON OCTOBER 23 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: email@example.com Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se
Auction details treasury bills21.10.2020 16:20:00 CEST | Press release
Auction date October 28, 2020 Maturity date Issue volume, SEK million Days (Act/360) ISIN code 2021-03-17 10,000 138 SE0014453890 Settlement date October 30, 2020 Bids have to be entered by 11.00 on October 28, 2020 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 Fo@riksgalden.se
Enento Group’s financial information 202121.10.2020 14:30:00 CEST | Press release
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 21 OCTOBER 2020 AT 3.30 P.M. EEST Enento Group’s financial information 2021 Enento Group Plc will publish its Financial Statements Bulletin for 2020 on Friday, 12 February 2021. The Annual Report and Financial Statements 2020 will be published in week 10 at https://enento.com/investors/ Enento Group’s Annual General Meeting is planned to be held on Monday, 29 March 2021. The notice to convene the Annual General Meeting will be given later on by the Board of Directors. Enento Group’s financial reporting in 2021 Financial Statements Bulletin for 2020 on Friday, 12 February 2021Interim Report for January – March 2021 on Thursday, 29 April 2021Half Year Financial Report for January – June 2021 on Wednesday, 21 July 2021Interim Report for January – September 2021 on Friday, 29 October 2021 All financial reports are published in English and Finnish and they are also available at https://enento.com/investors/ after the publication. ENENTO GROUP PLC For